down arrow

Cue Biopharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US22978P1066
USD
0.55
0 (-0.76%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Cue Biopharma, Inc.
Immunome, Inc.
NGM Biopharmaceuticals, Inc.
Aadi Bioscience, Inc.
Sonnet BioTherapeutics Holdings, Inc.
Armata Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
Theseus Pharmaceuticals, Inc.
Cyteir Therapeutics, Inc.
PepGen Inc.
Omega Therapeutics, Inc.
Why is Cue Biopharma, Inc. ?
1
Flat results in Jun 25
  • NET SALES(HY) At USD 3.38 MM has Grown at -22.86%
  • ROCE(HY) Lowest at -195.55%
  • CASH AND EQV(HY) Lowest at USD 40.63 MM
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -42.56%, its profits have risen by 18.8%
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -42.56% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Cue Biopharma, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Cue Biopharma, Inc.
-47.73%
-0.64
90.04%
S&P 500
12.66%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
15.63%
EBIT Growth (5y)
0.28%
EBIT to Interest (avg)
-44.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0.23
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
27.18%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.34
EV to EBIT
-1.02
EV to EBITDA
-1.09
EV to Capital Employed
42.11
EV to Sales
5.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4122.30%
ROE (Latest)
-616.78%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -28.15 MM

RAW MATERIAL COST(Y)

Fallen by -43.95% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -109.36 %

PRE-TAX PROFIT(Q)

Highest at USD -8.48 MM

NET PROFIT(Q)

Highest at USD -8.48 MM

EPS(Q)

Highest at USD -0.09

-8What is not working for the Company
NET SALES(HY)

At USD 3.38 MM has Grown at -22.86%

ROCE(HY)

Lowest at -195.55%

CASH AND EQV(HY)

Lowest at USD 40.63 MM

Here's what is working for Cue Biopharma, Inc.
Operating Cash Flow
Highest at USD -28.15 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit
Highest at USD -8.48 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -8.48 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.09
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio
Lowest at -109.36 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -43.95% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Cue Biopharma, Inc.
Net Sales
At USD 3.38 MM has Grown at -22.86%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Cash and Eqv
Lowest at USD 40.63 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."